Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06304246 |
Other study ID # |
FU-S.OZCAN 001 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
March 1, 2024 |
Est. completion date |
October 30, 2024 |
Study information
Verified date |
March 2024 |
Source |
Firat University |
Contact |
Sibel Ozcan, Associate Professor |
Phone |
+90-424-2370000-2977 |
Email |
s.ozcan[@]firat.edu.tr |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Adipokines are bioactive substances secreted from adipose tissue and have various functions
on appetite, energy, lipid, carbohydrate metabolism, regulation of blood pressure, and
inflammation. One of these is asprosin, discovered in 2016, which is secreted from white
adipose tissue. It has been shown that the level of asprosin encoded by the Fibrillin 1 gene
can vary in metabolic syndrome associated with obesity, diabetes, and insulin resistance .
Some adipokines such as leptin, adiponectin, or resistin are found in increasing levels in
the blood and placenta as pregnancy progresses. The detection of high concentrations of
adipokines in cord blood has shown that they play an important role in fetal development and
metabolism, can interfere with placental development, and affect pregnancy outcomes and fetal
growth. Adipokines associated with appetite, energy, lipid, and carbohydrate metabolism have
been shown to be effective in modulating pain in recent years. High levels of leptin have
been shown to be associated with decreased preoperative pain threshold and increased
postoperative analgesic consumption. Recent studies have indicated that asprosin also
exhibits analgesic effects in neuropathic pain models and may have clinical benefits in
alleviating chronic pain associated with diseases and injuries originating from peripheral
structures.
It is known that one of the most important factors affecting mothers' approach to
anesthesia technique in Cesarean section is their fear of intraoperative and postoperative
pain. Almost one in five patients experiences severe acute pain after Cesarean section. Pain
can be perceived differently by patients, and even with the same anesthesia technique, some
patients may experience more severe pain. Patients' perception of pain is influenced
by many factors such as pain threshold, mood, hormonal balance, central sensitization, and
genetic factors.
We hypothesized that the increased preoperative serum asprosin levels might be associated
with increased acute labor pain and that asprosin levels might lead to increased analgesic
use in the postoperative period. Additionally, we assumed that patients could alter their
preoperative pain threshold and report higher pain scores after surgery due to hyperalgesia
caused by high asprosin levels.
In this study, we aimed to investigate preoperative serum asprosin levels in patients
undergoing Cesarean section with and without acute labor pain and to determine whether there
is a relationship between preoperative asprosin levels and postoperative analgesic use.
Description:
Subjects: A total of 50 pregnant women, who are scheduled for elective cesarean section and
request spinal anesthesia for cesarean surgery, will be enrolled in the study. Patients will
be divided into two groups as follows: the labor pain group (LPG, pregnant women who will
undergo emergency C-section with labor pain) and the no pain group (NPG, pregnant women who
will undergo elective C-section without labor pain). Labor pain will be defined as having 3
or more regular uterine contractions in 20 minutes or >120 Montevideo units of uterine
performance observed during non-stress testing (NST) conducted at the Obstetrics Clinic.
Patients under the age of 18, those with preeclampsia, eclampsia, gestational diabetes, or
hypertension, patients with abnormal pregnancies, systemic diseases, or diabetes will be
excluded from the study.
Patient characteristics such as age, height, weight, body mass index, ASA and Mallampati
scores, gestational week, previous cesarean section count, existing medical conditions,
family history, smoking and alcohol use status, and pregnancy-related conditions and
complications will be recorded.
Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the
preoperative waiting room before the application of spinal anesthesia. The blood samples will
be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels.
Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in
the non-dominant hand of patients in the preoperative waiting room prior to spinal
anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant
hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when
the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three
times for each patient, and the average will be recorded as the pain threshold value.
Postoperative Pain Severity: Postoperative pain severity will be evaluated using the visual
analog scale (VAS). Before the evaluation, patients will be informed about the VAS and its
pain scoring system, which ranges from 0 (no pain) to 10 (extreme pain). All patients will be
monitored carefully, and their VAS scores will be recorded at 1, 2, 4, 6, 12, and 24 h
postoperatively.
Consumption of Postoperative Analgesic: For postoperative analgesia, patients will be
provided with tramadol-based patient-controlled analgesia. The time of the first analgesic
requirement and the total amount of analgesic used after 24 hours will be recorded.
Statistics: Continuous variables will be expressed as mean ± standard deviation. The normal
distribution of numerical variables will be checked using the Kolmogorov-Smirnov test.
Independent sample t-test will be used for comparing two independent groups when data are
normally distributed, and the Mann-Whitney U test will be used when data are not normally
distributed. Spearman's rho correlation coefficient will be used to examine the
relationships between asprosin levels, pain threshold, VAS score, and analgesic consumption.
Multiple regression analysis will be performed to examine the effects of asprosin levels and
group variables on analgesic consumption and pain threshold. P <0.05 will be considered
statistically significant for all analyses.